NaaS gets Nasdaq notification regarding minimum market value deficiency
Confident Investing Starts Here:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
US stock futures steady as investors await monthly labor data
By Sruthi Shankar and Nikhil Sharma (Reuters) -U.S. stock index futures held steady on Thursday as investors awaited monthly jobs data for insights on the health of the labor market and the Federal Reserve's plans for monetary easing. The S&P 500 and Nasdaq closed at record highs after Wednesday's choppy session, boosted by gains in technology stocks and a trade agreement between the United States and Vietnam that eased concerns about prolonged tariff tensions. The blue-chip Dow closed 1.35% below all-time highs touched in December. The nonfarm payrolls report for June is scheduled to be released at 8:30 a.m. ET (1230 GMT) - a day earlier than usual because the U.S. markets are closed on July 4 for Independence Day. Trading volumes are expected to be light, with markets closing early, at 1 p.m. ET on Thursday. The data is expected to show the U.S. labor market slowed further in June, with the unemployment rate expected to have edged up to more than a three-and-a-half-year high of 4.3%, as economic uncertainty stemming from the Trump administration's policies curbed hiring. Analysts forecast a rise of 110,000 jobs in the previous month, compared with 139,000 in May. "Chair (Jerome) Powell, leading the camp for the Fed to keep rates on hold, argues that sticky inflation and a solid labor market mean that the policy rate should be kept mildly restrictive," ING analysts said in a note. "Clearly, any downside surprise in the jobs report would weaken his (Powell's) position and allow the market to push on with pricing a rate cut at the July meeting." Traders are attaching a 25.3% chance of the U.S. Federal Reserve cutting interest rates at the July meeting, according to CME Group's Fedwatch tool, up from 20.7% a week ago. U.S. stocks dipped briefly on Wednesday after data showed private payrolls fell in June for the first time in more than two years. Other economic data on Thursday includes weekly jobless claims and the S&P Global and ISM services sector activity readings for June. Meanwhile, Republicans in the U.S. House of Representatives advanced President Donald Trump's massive tax-cut and spending bill toward a final yes-or-no vote, appearing to overcome internal party divisions over its cost. The legislation is expected to add $3.4 trillion to the nation's $36.2 trillion in debt over the next decade, according to nonpartisan analysts. At 07:07 a.m. ET (1107 GMT), S&P 500 E-minis were up 3.75 points, or 0.06%, Nasdaq 100 E-minis were up 16.75 points, or 0.07%, and Dow E-minis were up 42 points, or 0.09%. Shares of chip design software firms Synopsys and Cadence Design Systems climbed 6.1% and 5.9%, respectively, in premarket trading after the U.S. lifted export restrictions on chip design software to China, signaling a thaw in trade tensions between the world's top two economies. Tripadvisor climbed 6.5% after the Wall Street Journal reported activist investor Starboard Value had built a more than 9% stake in the online travel firm. Datadog jumped 9.6% after the cloud security firm was set to replace Juniper Networks on the S&P 500.
Forbes
36 minutes ago
- Forbes
AI For Small Business: A Practical Starting Point For Owners And Teams
Bernardo Martinez is the managing director at Inverdeco, Inc., an advisory firm. As a mentor and advisor to small businesses, I've been exploring how artificial intelligence (AI) can support entrepreneurs. I have used it internally to streamline work, speed up early drafts and support decision-making. The tools continue to improve incredibly fast, but the core challenge for many business owners hasn't changed. There is not enough time and money to execute another activity. The question I hear most often is simple: Can small businesses actually make use of AI in a meaningful way? The answer is yes, but only if it is done thoughtfully. AI can help small teams save time, improve consistency and gain leverage. But it takes intention, a clear starting point and a willingness to learn. AI can save time, but you'll need to make time first. Running a small business does not leave much extra room. Most owners wear multiple hats, managing operations, sales, hiring and customer service—often all at once. So the idea of learning a new technology, especially one as hyped as AI, may feel unrealistic or distracting. But there is a trade-off to consider. A 2024 survey found that 75% of small-business employees said AI helped them work more efficiently, and over half said it led to measurable cost savings. The challenge is finding the time up front to get those benefits later. That is why I often recommend starting small. Identify one task that feels repetitive or time-consuming—like writing emails, sorting data or summarizing internal notes—and explore whether AI can help with just that. An hour or two spent testing a tool could save multiple hours each week moving forward. AI can fill knowledge gaps, but it still needs your input. One of the most powerful aspects of AI is that it helps small teams get started in areas where they may not have in-house expertise. You do not need to be a marketer, analyst or writer to generate a solid first draft of a proposal, a campaign or a customer message. AI can help you move faster, with fewer resources. But it does not replace your knowledge of the business. In my experience, AI can take a task 80% to 90% of the way, but the last 10% still matters. Whether it is tone, context, accuracy or alignment with your goals, the final result usually needs your judgment. That is where prompting comes in—asking the tool the right questions, giving it the right context and knowing when to make adjustments. It is not about being technical. It is about being clear and thoughtful. Small businesses that treat AI as a support tool—not a decision-maker—get the most out of it. It is there to accelerate your work, not replace it. Time and money are tight, so be intentional. One of the biggest hurdles I see with small businesses is that both time and money are limited. You are juggling immediate needs—sales, customer service, staffing—while also trying to plan for the future. So when something like AI comes along, it is easy to feel like it is either out of reach or simply not urgent. That is why it is important to approach AI with clear priorities. Start by asking: Where are we spending too much time for too little return? That might be manually answering the same customer questions, rewriting similar emails or organizing data that never quite gets used. Once you have identified a few of those pain points, the next step is not to implement the perfect AI solution—it is to run a small, focused test. Try one tool, on one task, for a few weeks. Then step back and ask: Did it save us time? Did it help us work better? Was it worth the cost, even if small? You do not need a large budget to start, but you do need to make the effort count. When time and money are both tight, the goal is not to do more—it is to spend better. The most successful small businesses I have worked with do not chase every trend. They look for the few changes that free up their teams to focus on what matters most. Assign ownership even if it's a small role. For AI to gain traction in any business, someone needs to take ownership. That does not necessarily mean hiring a specialist. Often, it is enough to give a curious team member the space to explore and share what they learn. If that is not feasible internally, you can bring in light external support—a freelancer, a peer or an advisor—to help you get started. Even a few hours of input can point you toward the right use cases and help you avoid common missteps. The important thing is that AI is not treated as an afterthought. Moreover, it cannot be postponed. When it is a clear priority, even at a small scale, it tends to stick. Act now, start small, learn fast and stay focused. AI is not a silver bullet, but it is also not just a trend. It is becoming a practical tool for small businesses that are willing to approach it with focus. If you are not sure where to start, I would suggest the following steps: • Identify one task that eats up time every week. • Explore one way to automate or speed it up. • Test for two weeks. • If it works, keep going. If it does not, try something else. You do not need to 'adopt AI' as a strategy. You just need to use it where it helps. In my experience, the biggest wins come not from doing more but from doing what matters—better, faster and with more confidence. The information provided here is not investment, tax or financial advice. You should consult with a licensed professional for advice concerning your specific situation. Forbes Finance Council is an invitation-only organization for executives in successful accounting, financial planning and wealth management firms. Do I qualify?
Yahoo
40 minutes ago
- Yahoo
INOVIO Announces Pricing of $25 Million Public Offering
PLYMOUTH MEETING, Pa., July 3, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common stock and accompanying Series A warrants to purchase up to 14,285,715 shares of its common stock (or pre-funded warrants in lieu thereof) at an exercise price of $1.75 per share of common stock and Series B warrants to purchase up to 14,285,715 shares of its common stock (or pre-funded warrants in lieu thereof) at an exercise price of $1.75 per share of common stock, at a combined public offering price of $1.75 per share of common stock and accompanying Series A and Series B warrants. All of the securities in the offering are being sold by INOVIO. The offering is expected to close on or about July 7, 2025, subject to the satisfaction of customary closing conditions. INOVIO also granted the underwriters an option for a period of 30 days to purchase up to 2,142,857 additional shares of the Company's common stock and Series A warrants to purchase up to 2,142,857 additional shares of its common stock and Series B warrants to purchase up to 2,142,857 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by INOVIO, excluding any exercise of the underwriters' option to purchase additional securities and assuming no exercise of the accompanying Series A and Series B warrants, are expected to be approximately $25 million. Piper Sandler & Co. is acting as sole active book-running manager for the offering. Oppenheimer & Co. Inc. is also acting as a passive bookrunner for the offering. A shelf registration statement relating to the shares of common stock and accompanying Series A and Series B warrants offered in the offering described above was filed with the Securities and Exchange Commission ("SEC") on November 9, 2023 and declared effective by the SEC on January 31, 2024. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering were filed with the SEC and are available on the SEC's website at Copies of the final prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting: Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, or by telephone at (800) 747-3924, or by e-mail at prospectus@ and Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004, or by telephone at (212) 667-8055, or by e-mail at EquityProspectus@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About INOVIO INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. Forward-Looking Statements This release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include, but are not limited to, statements regarding the public offering of INOVIO's securities, including the timing of the closing of the offering, as well as the anticipated proceeds of the offering. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in INOVIO's Annual Report on Form 10-K for the year ended December 31, 2024, INOVIO's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 and in other filings that INOVIO makes with the SEC from time to time. There can be no assurance that any of the forward-looking information provided herein will be proven accurate. These forward-looking statements speak only as of the date hereof and INOVIO undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. Contacts Media: Jennie Willson (267) 429-8567 Peter Vozzo, ICR Healthcare, 443-213-0505 View original content to download multimedia: SOURCE INOVIO Pharmaceuticals, Inc. Sign in to access your portfolio
